Showing results (2231-2240 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|February 20, 2008
CPT21, a novel compound with anti-proliferative effect against gastric cancer cell SGC7901Bo Zhang, Yu Luo, Qinjie Weng, et al.
Investigational New Drugs|January 22, 2008
Identification of small molecules inducing apoptosis by cell-based assay using fission yeast deletion mutantsKyung-Sook Chung, Nam-Hui Yim, Seung-Hee Lee, et al.
Investigational New Drugs|December 1, 1988
Preclinical antitumor activity of 5-aza-2'-deoxycytidine against human and neck cancer xenografts [corrected]B J Braakhuis, G A van Dongen, M van Walsum, et al.
Investigational New Drugs|February 28, 2014
A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancerJeeyun Lee, Sang Joon Shin, Ik Joo Chung, et al.
Investigational New Drugs|February 19, 2014
Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumorsRamón Salazar, Antonio Calles, Marta Gil, et al.
Investigational New Drugs|March 3, 2019
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumorsJih-Hsiang Lee, Tom Wei-Wu Chen, Chih-Hung Hsu, et al.
Investigational New Drugs|March 3, 2019
A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancerXiaoli Liu, Wei Wang, Yanping Yin, et al.
Investigational New Drugs|December 1, 1987
Arabinosyl-5-azacytosine: a novel nucleoside entering clinical trialsJ L Grem, D D Shoemaker, D F Hoth, et al.
Investigational New Drugs|April 12, 2017
Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patientsValentine Heidelberger, François Goldwasser, Nora Kramkimel, et al.
Investigational New Drugs|June 14, 2008
O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanomaNicolas Penel, Corinne Delcambre, Xavier Durando, et al.
Pageof 372